Lupin announced that it has launched Rivaroxaban tablets USP, 2.5 mg, in the US market following final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug ...

Are you experiencing leg pain, numbness, or slow-healing wounds? 🦵 These could be warning signs of Peripheral Artery Disease ...

Peripheral artery disease, also known as PAD, is a condition in which the narrowing of the arteries causes poor blood flow to ...

Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a ...

Johnson & Johnson MedTech‘s Shockwave Medical announced the U.S. launch of its Javelin peripheral intravascular lithotripsy ...

The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday.

Johnson & Johnson MedTech’s Shockwave Medical is launching a new intravascular lithotripsy catheter in the U.S. | While ...

A scientific statement regarding pain and treatment considerations in patients with PAD has been published by the AHA.

Background Effective management of coexisting heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes mellitus ...

Shockwave Medical, Inc., part of Johnson & Johnson MedTech, announced the United States launch of the Javelin peripheral ...

Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This YearThis ...